Latest ZS AccessMonitor asks, 'Who are [physicians] listening to?'
    The annual update from ZS Associates (Chicago), a consulting firm on sales and related practices in life sciences, finds that 51% of physicians were considered "accessible" this year, as compared to 55% in 2013. "Though this year's drop was less precipitous than in previous years, it reflects the steady decline in access over the past decade," concludes the report. Data are based on call reports for over 200 pharma sales teams, meeting with approximately 325,000 prescribers. "Accessible" means those who were not either "access restricted" (who met with 31-70% of the reps who called on them) or
    Dispute continues the ongoing battles between drug distributors and DEA
    According to statements from the US Attorney, Northern District of California, and FedEx, the US Dept. of Justice is charging FedEx with "conspiracy to traffic in controlled substances," mostly arising from the practice, common several years ago but less so now, of handling shipments from online "pharmacies" (many of which are not actually pharmacies) that sell controlled substances and other drugs to US consumers directly. FedEx is entangled in this dispute because it handled the shipments, which date back to 2004. "FedEx is innocent of the charges ... we will plead not guilty
    Siren Interactive hires more executives, moves to downtown Chicago
    Siren Interactive, a relatively small agency specializing in rare-disease therapies marketing, is taking some big steps forward as its business continues to grow. The company has hired Suzanne Tsuchiya, an industry veteran formerly with the agencies Abelson Taylor and closerlook, as president; also Neil Rubenstein, a 15-year veteran of the agency business, as senior manager, media and analytics. Two other appointments were also announced. Wendy White, founder of Siren, remains as CEO; this year she is also the president-elect of the Healthcare Businesswomen's Assn.,
    After patent expiries, 'The industry has turned a corner'
    The World Preview 2014 from Evaluate Pharma (US HQ: Boston) totes up current worldwide pharma sales, assesses pipeline products, and projects industry growth to 2020. According to Paul Hills, head of operations, the "quality" (i.e., projected market value) of new drugs approved by FDA in 2013 increased by 43% over the previous year; this marks a "step change in innovation and output for the industry since 2009." Nine of the top ten introduced that year (led by Gilead Science's Sovaldi) will
    Meanwhile, competitor CSafe Global broadens its containers' usability
    The active-powered unit-load device (ULD) for shipping temperature-controlled products was pioneered by Envirotainer (Upplands Vasby, Sweden) years ago, but its use by air carriers has been limited to flights originating outside the US because it lacked FAA approval. Now, the company has been granted FAA approval for its RKN unit, putting it in direct competition with CSafe Global (Dayton, OH), whose RKN unit has been approved by both FAA and the European Aviation Safety Agency. The wider use of the Envirotainer ULD won't be immediate; the company says that a technical-acceptance process
    Deloitte veteran is a board director of the company
    Deloitte LLP (New York) has announced the appointment of Homi Kapadia, a 28-year veteran at the company, as leader of its life sciences industry practice, which employs nearly 4,000 professionals serving biopharma, med device and consumer health industries in the US. He takes over from Terry Hisey, principal, Deloitte Consulting LLP, who has transitioned to a top client-service position for the practice, according to a company statement. Kapadia will guide the practice to deliver a "cross sector" viewpoint to clients in light of their growing interdependency on other sectors as the health system converges around population health and value-based incentives
    European consumers will eventually have a pan-European method of checking pharmacy legitimacy
    Following through on one element of its comprehensive Falsified Medicinal Products Directive (2011/62/EU), the European Commission has selected a logo design that will appear on online-pharmacy websites and other retailers, starting roughly a year from now. The logo (pictured) is a stripe with a cross appearing in outline; the box in the middle left of the logo will have the flag of the EU country where the pharmacy is established. Behind the logo--still to be finalized
    San Francisco bounces back as No. 2; NJ/NYC/Westchester moves up to No. 5
    One of the highlights of the BIO international convention each year is the release of a report from JLL, the international commercial real-estate management and consulting firm, of its ranking of life sciences "clusters"--regions where life sciences companies tend to concentrate. Life sciences (biopharma, medical devices and crop science--the latter in keeping with the BIO organization's interests there) have been a preeminent attractor of state and regional economic development funds, in part because the lively venture-capital investing (especially of late) takes small labs to big manufacturing/research organizations with high-paying jobs
    CRM, master-data and related businesses will be purchased for $520 million
    IMS Health, which has been fairly active over the past year in acquisitions, leading to its IPO in April, has announced the acquisition of parts of Cegedim, the Paris-based IT and healthcare-data company. "Cegedim's complementary offerings will accelerate the build-out of our strategic roadmap in information and technology services," said Ari Bousbib, chairman and CEO of IMS. "The global combination of product, technology, infrastructure and people capabilities will bring compelling, integrated solutions to our clients and allow for greater operational efficiency." The $520-million deal is expected to close in early 2015. Bousbib focused on two assets
    Pharmaceutical Commerce's latest report finds continued growth in these specialized logistics services
    The 5th edition of the Biopharma Cold Chain Sourcebook analyzes economic, regulatory and technological trends in a vital part of today's industry: the shipment of temperature-controlled products. The just-published report calculates that current (2014) expenditures for commercial shipments will be $8.36 billion, rising to $10.28 billion in 2018. By comparison, last year's Sourcebook estimated the 2013 cold-chain business to be $7.5 billion, rising
Pharmaceutical Commerce
Digital Edition
Current Digital Edition
Read the July/August 2014 Issue now - It's Free!
Family of GTS Carry Packs handles drugs that patients self-administer
July 29-31, 2014
July 30 - August 2, 2014
August 12-13, 2014
August 23-26, 2014
September 3-5, 2014
September 8-10, 2014
Pharmaceutical Commerce sat down with Angela Miccoli, president of Cegedin Relationship Management NA, to talk about sales force automation, customer relationship management and multichannel marketing. Here’s what she had to say.
The eye-popping price tag on the hepatitis C drug, from Gilead Sciences, has prompted unprecedented pushback from payers  continued >
How to prepare for reporting and utilizing published data for business and compliance purposes  continued >
Setting a foundation for long-term success: How the pharmaceutical industry can transform Big Data into actionable insight  continued >
Global industry will spend $8.36 billion on cold chain logistics this year  continued >
A rising flow of new, expensive therapies is transforming relationships among payers and providers. Manufacturers will have to react nimbly to the changes  continued >
US pharma layoffs do not reflect the industry's health
The perverse fascination that the business press has with pharma layoffs masks the industry's underlying strength
Veeva survey finds wide disparities among trial operators and sites in managing clinical data
  |     |     |     |     |     |  
©2014 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by Offenberger & White.